Researchers on Wednesday reported two promising new approaches to counteract malaria's growing resistance to medication — one ...
The drug, known as GanLum, is made by Swiss pharmaceutical giant Novartis. In a late-stage trial, it worked about as well as ...
Hundreds of malaria patients enrolled in a phase 3 clinical trial in Gabon, West Africa, were successfully treated with a one ...
News Medical on MSN
Single-dose malaria treatment using four drugs achieves high cure rates in clinical trial
Hundreds of malaria patients participating in a Phase 3 clinical trial in Gabon in West Africa were cured via a single dose ...
Oct. 16—The Tripler Army Medical Center today confirmed it recently admitted and released a patient with malaria following successful treatment. The patient developed malaria symptoms following ...
Malaria is caused by a single-celled parasite of the genus Plasmodium. The parasite is transmitted to humans most commonly through mosquito bites. The malaria parasites enter the bloodstream and ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...
The patient traveled internationally and developed malaria symptoms upon return to the United States. Tripler advised that malaria is not spread person-to-person so there is “no immediate concerns for ...
allAfrica.com on MSN
No, bitter leaf cannot cure malaria – ignore dangerous claims and seek verified medical treatment
According to posts doing the rounds on Facebook in South Africa, bitter leaf is rich in quinine, a compound which can “cure malaria”. “It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback